BioCardia, Inc. · NASDAQ:BCDA

BioCardia — Investor Presentation (June 2021)

27 slides from BioCardia's investor presentation, June 2021

  1. Slide 1: Corporate Presentation

    Bringing personalized medicine to cell therapy for heart disease Corporate Presentation BioCardia, Inc. (NASDAQ: BCDA) http://www.biocardia.com/ 05295-M (MKT) Corporate Presentation 2021 Q2

  2. Slide 2: Presentation Content and Forward-Looking Statements

    Presentation Content and Forward-Looking Statements Presentation Content No part of this presentation or the information herein may be reproduced, photocopied, redistributed or passed on, directly or indirectly, to any other person, or published, in whole or in part, for any purpose without the cons

  3. Slide 3: Advanced and Capital Efficient Pipeline of Autologous and Allogenic Cell Therapies

    Advanced and Capital Efficient Pipeline of Autologous and Allogenic Cell Therapies for Cardiovascular and Respiratory Diseases Product Candidate 2021 (Pathway) Preclinical Phase 1 Phase 2 Phase 3 Milestone Autologous CardiAMP® for Ischemic Heart Failure Q2 DSMB uses Helix BCDA-01 Readout Funded Auto

  4. Slide 4: Selected financial data shows strong balance sheet with modest burn rate

    Selected financial date shows Strong balance sheet with modest burn rate BioCardia, Inc. (NASDAQ: BCDA) Quarter Ended Year Ended Year Ended Year Ended 31-Mar-21 31-Dec-20 31-Dec-19 31-Dec-18 Revenues $46,000 $145,000 $710,000 $625,000 Net Loss $3.0M $15.0 M $14.7M $14.0M Cash used in $1.9M $12.4 M $

  5. Slide 5: Problem: Heart failure is an Enormous Unmet Disease

    Problem: Heart failure is an Enormous Unmet Disease • Affects more than 26 million people worldwide, with 50% mortality at five years. • No existing therapies are curative, they currently only slow disease progression. • Recent data shows newer meds only reduce mortality by 0.9% (sodium glucose co t

  6. Slide 6: Potential of Bone Marrow Cells Delivered Locally to the Heart

    Potential of Bone Marrow Cells Delivered Locally to the Heart  Bone marrow cells home to the heart in injury  Cells include a number of important cell populations (CD34+, CD19+, CD133+, MSC) that have each shown benefit for treating the heart in animal and clinical studies  Significant evidence o

  7. Slide 7: Potential Heart Failure Solution in CardiAMP Cell Therapy (BCDA-01)

    Potential Heart Failure Solution in CardiAMP Cell Therapy (BCDA-01) FDA CBER regulated as device system. Medicare reimbursement established for two pivotal trials. 05295-M (MKT) Corporate Presentation 2021 Q2 7

  8. Slide 8: CardiAMP Cell Therapy is a Significant Advance

    CardiAMP Cell Therapy is a Significant Advance The 1st cardiac cell therapy that combines a pre-procedural assay, point of care cell processing system and transendocardial delivery system. How is it unique from other cardiac cell therapies? 1st test for a cardiac cell therapy that Patient Selection

  9. Slide 9: Pre-procedure Screening Selects Patients Likely to Respond

    CardiAMP Pre-procedure Screening Selects Patients Likely to Respond, Assay Performed in CLIA/CAP Laboratory  CardiAMP Potency Assay bone marrow biomarker panel analysis at core lab: Anticipated to select 70% most likely to respond based on therapeutic potential of their bone marrow  One marker is

  10. Slide 10: Cell Processing for Transfer at Point of Care

    CardiAMP Cell Processing for Transfer at Point of Care with Proprietary FDA Cleared, CE Marked, and Japan Approved Devices Provides for a 5cc dosage form with a target dosage of 200 million cells. Superior recovery of mesenchymal stem cells and endothelial progenitor cells. 05295-M (MKT) Corporate P

  11. Slide 11: Cell Delivery to Damaged Regions of Heart with Proprietary Helix System

    CardiAMP Cell Delivery to Damaged Regions of Heart with Proprietary Helix System, Approved in Europe Target dosage is delivered to ten sites in the heart around the infarct zone. 05295-M (MKT) Corporate Presentation 2021 Q2 11

  12. Slide 12: Proprietary Helix System Delivers Directly to Target Sites in Heart

    Proprietary Helix System Delivers Directly to Target Sites in Heart Video showing Helix performance in large animal model. 05295-M (MKT) Corporate Presentation 2021 Q2 12

  13. Slide 13: CardiAMP HF Phase I Trial Design and Results

    CardiAMP HF Phase I Trial Design and Results Transendocardial Autologous Bone Marrow in Myocardial Infarction (TABMMI) NCT00507468 Safety: No Treatment Emergent-MACE 20 Ischemic Heart Failure Patients LVEF<40% NYHA Class I, II, and III Open Label Safety Study 100 Million BMC 10 peri-infarct injectio

  14. Slide 14: CardiAMP HF Phase II Trial Design and Results

    CardiAMP HF Phase II Trial Design and Results Transendocardial Autologous Cells in Heart Failure Trial (TAC-HFT), NCT00768066 Primary safety endpoint was met: no treatment-emergent MACE at 30 days pp; no death or MACE in BMC treatment group at one year follow-up All secondary efficacy endpoints at

  15. Slide 15: CardiAMP HF: Phase 3 Pivotal Trial to Support FDA Approval

    CardiAMP HF : Phase 3 Pivotal Trial to Support FDA Approval 250 Ischemic Heart Failure Patients Changes from Phase II: NYHA Class I patients 20% ≤ Left Ventricular Ejection Fraction ≤ 40% eliminated and potency assay is implemented NYHA Class II and III with intent to enhance CardiAMP Potency Assay

  16. Slide 16: HF Phase 3 Pivotal Trial Results To Date

    CardiAMP HF Phase 3 Pivotal Trial Results To Date  Three Data Safety Monitoring Board (DSMB) pre-specified interim analysis have been performed. No safety concerns have been identified. Most recently in December 2020, the DSMB looked at 86 patients enrolled * Statistically significant and also perf

  17. Slide 17: HF Phase 3 Pivotal Trial Results To Date

    CardiAMP HF Phase 3 Pivotal Trial Results To Date Change in Akinetic Wall Segments 0 Δ Akinetic Segments -1.1 TACHFT -1 Phase II Results +0.97 % -1.9 -2 p=0.08 -3 p=0.04 -4 Baseline 6 Months 12 Months Echo Core Lab (Yale School of Medicine) Change in Wall Motion Score 0 Sources of data and additiona

  18. Slide 18: CardiAMP 2nd Indication: Chronic Myocardial Ischemia (BCDA-02)

    CardiAMP 2nd Indication: Chronic Myocardial Ischemia (BCDA-02) Burden of Illness and Unmet Need  Patients suffer from poor perceived health status and psychological distress, have significant impairment in quality of life, and represent a burden to the healthcare system due to significant use of re

  19. Slide 19: BCDA-02 Approved by FDA, First Site Activation

    CardiAMP 2nd Indication: Chronic Myocardial Ischemia (BCDA-02) Approved by FDA, First Site Activation Q2 2020 CardiAMP Chronic Myocardial Ischemia Trial, NCT03455725, IDE Trial for Premarket Approval 40 centers, 343 Chronic Myocardial Ischemia Patients Open Label Roll In 200M Cells (N=10) Randomized

  20. Slide 20: Alternate HF Therapy: CardiALLO Cell Therapy (BCDA-03)

    Alternate HF Therapy: CardiALLO Cell Therapy (BCDA-03) Initially Targeting Ischemic Heart Failure Patients Excluded from CardiAMP Burden of Illness and Unmet Need  Chronic disease with 50% mortality at five years, impacts 1 in 5 adults over age of 40.  Annual cost estimated to be $39 billion, proj

  21. Slide 21: Alternate HF Therapy: NK1R+ Mesenchymal Stem Cell Therapy (BCDA-03)

    Alternate HF Therapy: Neurokinin 1 Receptor Positive Mesenchymal Stem Cell Therapy (BCDA-03) Three BioCardia co-sponsored culture expanded Path forward is clear and based on clinical mesenchymal cell clinical trials in heart failure experience and rigorous data have been completed and published:  S

  22. Slide 22: Three Commercially Viable and Potentially Pivotal Cardiac Programs

    Three Commercially Viable and Potentially Pivotal Cardiac Programs CardiAMP cell therapy (BCDA-01, 02)  Regulated and manufactured as a procedure kit with anticipated low cost of goods and long shelf life  For both leading indications, CardiAMP fits into standard interventional cardiology device c

  23. Slide 23: Allogenic NK1R+ MSC (BCDA-04) Potential for Inflammatory Respiratory Disease

    Allogenic Neurokinin 1 Receptor Positive MSC (BCDA-04) Potential for Inflammatory Respiratory Disease  The anti-inflammatory effects of MSC have been well-documented and MSC have been shown to reduce inflammation and injury in models of  . lung disease. The specific MSCs used in BioCardia’s alloge

  24. Slide 24: Intellectual Property Overview

    Intellectual Property Overview  Exclusive rights to over 65 patents and patent applications in USA, Europe, China, India, and Japan covering CardiAMP Cell Therapy, CardiALLO Cell Therapy, Helix biotherapeutic delivery system and Morph vascular access catheter products.  Ten most recently issued US

  25. Slide 25: Leadership Team Advancing Autologous and Allogenic Cell Therapies

    Leadership Team Advancing Autologous and Allogenic Cell Therapies for Cardiovascular and Respiratory Indications Peter Altman, David Ian Sujith Debby Edward PhD McClung McNiece, Shetty, MD Holmes- Gillis PhD Higgin CEO Chief Chief Chief VP SVP Financial Scientific Medical Clinical Devices Officer Of

  26. Slide 26: Significant Anticipated Milestones in 2021

    Significant Anticipated Milestones in 2021 • BCDA-01, our CardiAMP autologous cell therapy under Phase III clinical development for the treatment of ischemic heart failure remains the Company’s top priority. The Company is targeting completion of enrollment without requiring additional financing. Th

  27. Slide 27: Thank you.

    Thank you. Peter Altman, PhD Chief Executive Officer NASDAQ: BCDA 05295-M (MKT) Corporate Presentation 2021 Q2 27

BioCardia — Investor Presentation (June 2021) on 6ix